Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Oncogene. 2020 Feb 15;39(14):3015–3027. doi: 10.1038/s41388-020-1201-z

Table 1.

IC50 of MTT and CFU (Mean ± SD) of TP53-mutated and -wild type AML cells treated with Echinomycin

TP53-mutated AML TP53-wild type AML
AML-12 AML-83 AML-135 AML-147 AML-172 AML-253 AML-277 AML-71 AML-132
IC50 (MTT, nM) 3.021 ± 1.145 0.656 ± 0.061 2.017 ± 0.205 1.252 ± 0.325 2.405 ± 0.344 1.274 ± 0.148 2.075 ± 0.213 3.438 ± 1.295 3.276 ± 0.979
IC50 (CFU, nM) 0.152 ± 0.021 0.113 ± 0.067 0.232 ± 0.061 0.237 ± 0.014 0.376 ± 0.121 0.326 ± 0.078 0.833 ± 0.039 0.184 ± 0.179 0.175 ± 0.098